Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol

J. Stutterheim, P. de Lorenzo, I. M. van der Sluis, J. Alten, P. Ancliffe, A. Attarbaschi, L. Aversa, J. M. Boer, A. Biondi, B. Brethon, P. Diaz, G. Cazzaniga, G. Escherich, A. Ferster, R. S. Kotecha, B. Lausen, Alex WK Leung, F. Locatelli, L. Silverman, J. StaryT. Szczepanski, V. H.J. van der Velden, A. Vora, J. Zuna, M. Schrappe, M. G. Valsecchi, R. Pieters

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol'. Together they form a unique fingerprint.

Medicine & Life Sciences